MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Altimmune Inc

Fechado

4.44 -7.11

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.44

Máximo

4.72

Indicadores-chave

By Trading Economics

Rendimento

-335K

-23M

Vendas

5K

EPS

-0.33

Margem de lucro

-463,600

Funcionários

59

EBITDA

-344K

-23M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+357.32% upside

Dividendos

By Dow Jones

Próximos Ganhos

8 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-16M

410M

Abertura anterior

11.55

Fecho anterior

4.44

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Altimmune Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de abr. de 2025, 23:04 UTC

Principais Notícias

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 de abr. de 2025, 22:40 UTC

Grandes Movimentos do Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 de abr. de 2025, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 de abr. de 2025, 18:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 de abr. de 2025, 23:43 UTC

Conversa de Mercado

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 de abr. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 de abr. de 2025, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 de abr. de 2025, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 de abr. de 2025, 21:43 UTC

Principais Notícias
Ganhos

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

3 de abr. de 2025, 20:43 UTC

Conversa de Mercado

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 de abr. de 2025, 20:34 UTC

Principais Notícias

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 de abr. de 2025, 20:23 UTC

Principais Notícias

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 de abr. de 2025, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 de abr. de 2025, 19:55 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de abr. de 2025, 19:55 UTC

Conversa de Mercado

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 de abr. de 2025, 19:21 UTC

Conversa de Mercado

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 de abr. de 2025, 19:15 UTC

Conversa de Mercado

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 de abr. de 2025, 18:45 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 de abr. de 2025, 18:45 UTC

Conversa de Mercado

Gold Drops In Tariff Fallout -- Market Talk

3 de abr. de 2025, 18:39 UTC

Conversa de Mercado

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 de abr. de 2025, 18:38 UTC

Principais Notícias

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 de abr. de 2025, 18:30 UTC

Principais Notícias

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 de abr. de 2025, 18:20 UTC

Conversa de Mercado

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 de abr. de 2025, 18:18 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 de abr. de 2025, 18:17 UTC

Conversa de Mercado

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 de abr. de 2025, 18:04 UTC

Conversa de Mercado

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 de abr. de 2025, 17:55 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

Altimmune Inc Previsão

Preço-alvo

By TipRanks

357.32% parte superior

Previsão para 12 meses

Média 21.86 USD  357.32%

Máximo 28 USD

Mínimo 12 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Altimmune Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

7

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.7 / 5.88Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.